AR882 / Arthrosi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  AR882 / Arthrosi
    AR882, A SELECTIVE URAT1 INHIBITOR, EXHIBITS NO DRUG-DRUG INTERACTIONS WITH KEY RENAL, HEPATIC, AND GI TRANSPORTERS (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1891;    
    AR882 has been comprehensively evaluated for transporter-mediated DDI potential in vitro and in clinical studies, and exhibited no DDI concerns. These findings demonstrated that AR882 can be safely given in gout patients with various comorbid conditions including diabetes, hypertension and hyperlipidemia and the concomitant medications that are primarily cleared via transporters.
  • ||||||||||  AR882 / Arthrosi
    Trial completion date, Trial primary completion date, Combination therapy:  Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination with Allopurinol in Patients with Tophaceous Gout (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=42, Active, not recruiting, 
    AR882 may offer improved efficacy and better safety compared to existing therapies in the treatment of patients with gout, including those with both clinically visible and subclinical crystal deposition. Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
  • ||||||||||  AR882 / Arthrosi
    AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3228;    
    With its unique, slower elimination in PK, AR882 maintains a smooth intra-day uric acid excretion profile that was similar to baseline or to that in placebo patients, resulting in a lasting inhibitory effect without any high concentration of uric acid influx in the kidney tubules. The lack of daily transient increase in uric acid excretion confirms AR882, as a new uricosuric agent, possessing a favorable and safe renal profile over existing and other approved uricosuric agents.
  • ||||||||||  AR882 / Arthrosi
    Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3226;    
    In a subset of patients with full PK/PD collection, AR882 showed potent sUA lowering effect with similar exposures to those observed in closely monitored early-phase studies. AR882 50 mg and 75 mg doses were well tolerated during the entire study with an unremarkable safety profile.
  • ||||||||||  AR882 / Arthrosi
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination with Allopurinol in Patients with Tophaceous Gout (clinicaltrials.gov) -  Mar 17, 2023   
    P2,  N=42, Active, not recruiting, 
    AR882 may offer improved efficacy and better safety compared to existing therapies in the treatment of patients with gout including those with severe or refractory disease across various demographics and comorbidities. Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> Feb 2024
  • ||||||||||  AR882 / Arthrosi
    Trial completion:  Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients (clinicaltrials.gov) -  Jan 31, 2023   
    P2b,  N=140, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> Feb 2024 Active, not recruiting --> Completed
  • ||||||||||  AR882 / Arthrosi
    Trial completion date, Trial primary completion date:  Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients (clinicaltrials.gov) -  Jul 19, 2022   
    P2b,  N=120, Recruiting, 
    Recruiting --> Completed Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: May 2022 --> Sep 2022
  • ||||||||||  AR882 / Arthrosi
    Enrollment open:  Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients (clinicaltrials.gov) -  Dec 1, 2021   
    P2b,  N=120, Recruiting, 
    Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: May 2022 --> Sep 2022 Not yet recruiting --> Recruiting
  • ||||||||||  AR882 / Arthrosi
    Clinical, Journal:  Tatton-Brown-Rahman syndrome: Six individuals with novel features. (Pubmed Central) -  Feb 4, 2021   
    We present six individuals with TBRS, including the youngest individual thus far reported, first individual to be diagnosed with tumor testing and two individuals with variants at the Arg882 domain, bringing the total number of reported cases to 82...Four patients manifested symptoms suggestive of autonomic dysfunction, including central sleep apnea, postural orthostatic hypotension, and episodic vasomotor instability in the extremities. We discuss the molecular and clinical findings in our patients with TBRS in context of existing literature.
  • ||||||||||  AR882 / Arthrosi
    Trial completion:  Single-dose AME Study With [14C]AR882 in Healthy Male Subjects (clinicaltrials.gov) -  Aug 17, 2020   
    P1,  N=6, Completed, 
    Recruiting --> Completed | Trial primary completion date: Jun 2020 --> Sep 2020 Active, not recruiting --> Completed
  • ||||||||||  AR882 / Arthrosi
    Journal:  DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells. (Pubmed Central) -  Feb 6, 2020   
    DNA methyltransferase 3A (DNMT3A) is mutated in various myeloid neoplasms including AML, especially at the Arg882...In addition, human bone marrow AML cells carrying KMT2A-PTD/DNMT3A-MT showed abnormal growth and augmented self-renewal activity in primary cell culture. The present study provides information underlying the pathogenic role of DNMT3A-MT with KMT2A-PTD in proliferating advantage with augmentation of self-renewal activity in human leukemia, which may help to better understand the disease and to design better therapy for AML patients with these mutations.
  • ||||||||||  AR882 / Arthrosi
    Enrollment open, Combination therapy:  Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients (clinicaltrials.gov) -  Feb 5, 2020   
    P2a,  N=32, Recruiting, 
    The present study provides information underlying the pathogenic role of DNMT3A-MT with KMT2A-PTD in proliferating advantage with augmentation of self-renewal activity in human leukemia, which may help to better understand the disease and to design better therapy for AML patients with these mutations. Not yet recruiting --> Recruiting